Samuel P. Wertheimer, Ph.D., Private Equity Partner. Dr. Wertheimer joined OrbiMed in 2000 in the private equity funds management group. Dr. Wertheimer's prior experience includes work in biotechnology finance, technology transfer, intellectual property and research in immunology and molecular biology. Dr. Wertheimer was a Fellow at the Memorial Sloan-Kettering Cancer Center. Dr. Wertheimer received a Ph.D. in Molecular Biology from New York University, an M.P.H. from Yale University and a B.A. from The Johns Hopkins University. He has served as a Director of Salmedix and Corus Pharma and currently serves on the boards of several private biotechnology companies including ChemoCentryx, InteKrin and NeurAxon and publicly traded Biodel (NASDAQ: BIOD).

Back to Top

Robert Glassman, M.D., Private Equity Partner. Dr. Glassman joined OrbiMed in 2009, after an eight year tenure at Merrill Lynch & Co. where he was most recently a Managing Director in the healthcare investment banking group. Prior to his role in banking, he was a vice-president of private equity investments at Merrill Lynch Ventures, where he specifically oversaw healthcare investments. Before Merrill Lynch, Dr. Glassman was a consultant in McKinsey & Company's healthcare practice, where he served a variety of pharmaceutical, medical product, and provider clients. He has co-authored several articles in peer reviewed journals and spoken in industry and academic forums on drug commercialization, biotechnology innovation, oncology clinical development, biomarker utility, and pharmaceutical R&D. Dr. Glassman is a board certified hematologist-oncologist and clinical assistant professor at Weill-Cornell University Medical College and New York Presbyterian Hospital. He is a graduate of Harvard College and Harvard Medical School, did his residency in internal medicine at the Hospital of the University of Pennsylvania, and his fellowship in hematology and oncology at Cornell. He concurrently spent several years as a basic science investigator at Rockefeller University, where he held Howard Hughes Medical Institute and American Cancer Society awards.

Back to Top

Rishi Gupta, JD, Private Equity Principal. Mr. Gupta joined OrbiMed in 2003 to focus on private equity investments. Previously, he was a healthcare investment banker at Raymond James & Associates, served as Manager of Corporate Development at Veritas Medicine, and was a summer associate at Wachtell, Lipton, Rosen & Katz. Mr. Gupta has published scientific articles on the mechanisms of HIV entry into host cells and legal articles on intellectual property laws in the developing world. He received his A.B. degree magna cum laude in Biochemical Sciences from Harvard College and holds a J.D. from the Yale Law School. Mr. Gupta currently serves as a director on the boards of Sientra, Kreogene and Gelesis, and as an observer on the boards of Acceleron Pharma, Supernus Pharmaceuticals, Athersys and Apoptos. He is actively involved in OrbiMed's investments in Cerimon and InteKrin, and was formerly an observer on the board of CoGenesys (acquired by Teva, 2008).

Back to Top

David Bonita, M.D., Private Equity Principal. Dr. Bonita joined Orbimed in 2004 to focus on private equity investments and structured transactions in small capitalization public equity companies. Prior to joining Orbimed, Dr. Bonita worked as a corporate finance analyst in the healthcare investment banking groups of Morgan Stanley and UBS. He has also published scientific articles in peer reviewed journals based on signal transduction research performed at the Harvard Medical School. Dr. Bonita received his A.B. degree magna cum laude in Biological Sciences from Harvard University and his joint M.D./M.B.A. from Columbia University where he was elected to the Alpha Omega Alpha Medical Honor Society and Beta Gamma Sigma Business Honor Society. Dr. Bonita currently serves as a director on the board of ViewRay. He has also served or currently serves as an observer on the boards of Superdimension, Innovative Spinal Technologies, Enobia Pharma, and Insulet, and is actively involved in OrbiMed's investments in Volcano Corporation and Ambit Biosciences

Back to Top

Chau Q. Khuong, Private Equity Principal. Mr. Khuong joined OrbiMed in 2003 to focus on biotechnology and medical device investments into both private equity and small capitalization public companies. Mr. Khuong has had experience in start-up operations and business development at Veritas Medicine, basic science research at Yale School of Medicine and Massachusetts General Hospital, and was a summer associate in the New Ventures technology transfer group at Columbia University. Mr. Khuong holds a B.S. degree in Molecular, Cellular, and Developmental Biology (Concentration in Biotechnology) and a Master's in Public Health (Concentration in Infectious Disease), both from Yale University. He was actively involved in OrbiMed investments in Arius Research (acquired by Roche, 2008), Peninsula Pharmaceuticals (acquired by JNJ, 2005), Cerexa (acquired by Forest, 2007), Adiana (acquired by Cytyc, 2007), Biodel (NASDAQ: BIOD), and Emphasys Medical. Mr. Khuong currently serves on the Board of Directors at Cerapedics and is an Observer on the Board of Directors at Biolex, Glaukos, and Pieris AG.

Back to Top